Maralixibat

Mechanism :

Maralixibat is an inhibitor of ileal bile acid transporter (IBAT).

IBAT inhibitors act locally in the distal ileum to reduce the reuptake of bile acids and increase the clearance of bile acids through the colon thus decreasing the serum concentration of bile acids.

Indication :

• Cholestatic Pruritis (in patients aged more than 1 year of age with Alagille syndrome)

Contraindications :

• Contraindicated in patients with hypersensitivity to drug components

• Use cautiously in patients with a history of hepatic decompensation

• Use cautiously in patients with fat-soluble vitamin deficiency

Pregnancy: Limited data available regarding use in the course of pregnancy. Caution advised. Monitor fat-soluble vitamin levels if administered.

Lactation: Limited data available regarding use in the course of breastfeeding. Caution advised. Monitor fat-soluble vitamin levels if administered.

Dosing :

Adverse Effect :

GI bleeding, fat soluble vitamin deficiency, diarrhea, abdominal pain, vomiting, elevation of AST and ALT, nausea, bone fractures.